Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

548 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.
Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A. Staehler M, et al. Among authors: escudier b. Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329. Ann Oncol. 2018. PMID: 30412222 Free PMC article. Clinical Trial.
Super-high-risk germ-cell tumors: a clinical entity. Report of eleven cases.
Moran-Ribon A, Droz JP, Kattan J, Leclercq B, Ghosn M, Couanet D, Ostronoff M, Culine S, Misset B, Escudier B, et al. Moran-Ribon A, et al. Among authors: escudier b. Support Care Cancer. 1994 Jul;2(4):253-8. doi: 10.1007/BF00365732. Support Care Cancer. 1994. PMID: 8087445 Free article.
Cerebral vasculitis after interleukin-2 therapy for renal cell carcinoma.
Michel M, Vincent F, Sigal R, Damaj G, Bensousan TA, Leclercq B, Escudier B. Michel M, et al. Among authors: escudier b. J Immunother Emphasis Tumor Immunol. 1995 Aug;18(2):124-6. doi: 10.1097/00002371-199508000-00007. J Immunother Emphasis Tumor Immunol. 1995. PMID: 8574468
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie.
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T. Negrier S, et al. Among authors: escudier b. N Engl J Med. 1998 Apr 30;338(18):1272-8. doi: 10.1056/NEJM199804303381805. N Engl J Med. 1998. PMID: 9562581 Free article. Clinical Trial.
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie.
Ravaud A, Audhuy B, Gomez F, Escudier B, Lesimple T, Chevreau C, Douillard JY, Caty A, Geoffrois L, Ferrero JM, Linassier C, Drevon M, Négrier S. Ravaud A, et al. Among authors: escudier b. J Clin Oncol. 1998 Aug;16(8):2728-32. doi: 10.1200/JCO.1998.16.8.2728. J Clin Oncol. 1998. PMID: 9704724 Clinical Trial.
548 results